Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

Telaprevir for previously treated chronic HCV infection.

McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM; PROVE3 Study Team.

N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014. Erratum in: N Engl J Med. 2010 Apr 29;362(17):1647. Dosage error in article text.

PMID:
20375406
[PubMed - indexed for MEDLINE]
Free Article
2.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
[PubMed - indexed for MEDLINE]
3.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
[PubMed - indexed for MEDLINE]
4.

Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.

Burney T, Dusheiko G.

Expert Rev Anti Infect Ther. 2011 Feb;9(2):151-60. doi: 10.1586/eri.10.153. Epub 2010 Dec 14. Review.

PMID:
21143041
[PubMed - indexed for MEDLINE]
5.

Chronic hepatitis C: management of treatment failures.

Keeffe EB.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S102-5. Review.

PMID:
16234055
[PubMed - indexed for MEDLINE]
6.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
7.

Telaprevir user's guide.

Liapakis AM, Jacobson I.

Liver Int. 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. Review.

PMID:
22212567
[PubMed - indexed for MEDLINE]
8.

Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis.

Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N.

Pharmazie. 2012 Dec;67(12):963-72. Review.

PMID:
23346756
[PubMed - indexed for MEDLINE]
9.

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.

Singal AK, Jampana SC, Anand BS.

Dig Dis Sci. 2011 Aug;56(8):2221-6. doi: 10.1007/s10620-011-1765-0. Epub 2011 Jun 4. Review.

PMID:
21643737
[PubMed - indexed for MEDLINE]
10.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
[PubMed - indexed for MEDLINE]
11.

Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis.

Dang SS, Wang WJ, Wang XF, Li YP, Li M, Jia XL, Wang Y, Liu E, Zhao S.

Hepatogastroenterology. 2012 Mar-Apr;59(114):461-8. doi: 10.5754/hge11312. Review.

PMID:
21940388
[PubMed - indexed for MEDLINE]
12.

Telaprevir: an oral protease inhibitor for hepatitis C virus infection.

Kim JJ, Culley CM, Mohammad RA.

Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33. doi: 10.2146/ajhp110123. Review.

PMID:
22180548
[PubMed - indexed for MEDLINE]
13.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

PMID:
22296568
[PubMed - indexed for MEDLINE]
14.

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.

Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P.

Liver Int. 2010 Oct;30(9):1259-69. doi: 10.1111/j.1478-3231.2010.02283.x. Review.

PMID:
20633102
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.

Forestier N, Zeuzem S.

Liver Int. 2012 Feb;32 Suppl 1:44-50. doi: 10.1111/j.1478-3231.2011.02720.x. Review.

PMID:
22212571
[PubMed - indexed for MEDLINE]
16.

Optimal treatment with telaprevir for chronic HCV infection.

Jesudian AB, Jacobson IM.

Liver Int. 2013 Feb;33 Suppl 1:3-13. doi: 10.1111/liv.12079. Review.

PMID:
23286840
[PubMed - indexed for MEDLINE]
17.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
[PubMed - indexed for MEDLINE]
18.

Telaprevir for chronic hepatitis C virus infection.

Jesudian AB, Jacobson IM.

Clin Liver Dis. 2013 Feb;17(1):47-62. doi: 10.1016/j.cld.2012.09.010. Review.

PMID:
23177282
[PubMed - indexed for MEDLINE]
19.

Peginterferon and ribavirin for chronic hepatitis C.

Hoofnagle JH, Seeff LB.

N Engl J Med. 2006 Dec 7;355(23):2444-51. Review. No abstract available.

PMID:
17151366
[PubMed - indexed for MEDLINE]
20.

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Shiffman ML, Esteban R.

Liver Int. 2012 Feb;32 Suppl 1:54-60. doi: 10.1111/j.1478-3231.2011.02718.x. Review.

PMID:
22212573
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk